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Introduction
The literature demonstrates that only 31% of trials are
successful in recruiting 100% of their original target and
45% recruit fewer than 80% (McDonald, 2006). It has
been proposed that in prevention trials only one in
twenty of patients screened are enrolled into trials and
for medical care therapy trials the figure is nearer 1 in 5
(Spilker and Cramer, 1992).
Aims
To compare recruitment in therapeutic trials with that
in prevention trials to test Spilker and Cramer’s hypoth-
esis that there is a large difference between the two
types of studies.
Methods
Data from all stages of the recruitment process were
extracted from existing systematic reviews of prevention
and therapy RCTs focussing on the use of metformin
monotherapy in diabetes as a case study.
Results
Twenty six diabetes prevention and twenty- seven dia-
betes therapy papers were reviewed. The recruitment
yield, defined as the percentage of people recruited to
people screened, in the diabetes prevention studies was
11%. The recruitment yield of the diabetes therapy stu-
dies was almost five times higher at 53%.
Conclusions
Recruitment yields in prevention and therapy trials, were
higher than Spilker and Cramer’s predictions of 5% and
20% respectively. However, there is a large difference
between recruitment yields to the two types of studies and
this should be taken into consideration when estimating
recruitment rates for future trials. Reporting of data at all
stages in the recruitment process needs to be improved to
facilitate better estimation of recruitment yields.
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